FDA Approves First Narcolepsy Drug That Targets the Brain Signal Loss Behind the Disorder

Patient rests during hospital sleep evaluation. (Credit: Editorial Illustration via AI)

The Food and Drug Administration has approved the first medicine for narcolepsy type 1 that acts on the biological cause of the disorder rather than managing its symptoms separately, a shift the agency itself described as treating the condition as a whole.

The drug, oveporexton, will be sold as Orzeyful. It is an oral orexin receptor 2 agonist, meaning it selectively stimulates the brain receptor that people with narcolepsy type 1 can no longer activate normally because the neurons that produce orexin have been lost.